1. Search Result
Search Result
Results for "

complex V

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

2

Natural
Products

7

Recombinant Proteins

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-152949

    Myosin Neurological Disease
    Myosin V-IN-1 (compound 8) is a potent and selective Myosin V inhibitor, with a Ki of 6 μM. Myosin V-IN-1 shows acute inhibition of myosin V. Myosin V-IN-1 slows the actin-activated myosin V ATPase by specifically inhibiting ADP release from the actomyosin complex .
    Myosin V-IN-1
  • HY-130257

    PROTACs Cancer
    CP5V is a PROTAC connected by ligands for von Hippel-Lindau and CDK, which specifically degrades Cdc20 by linking Cdc20 to the VHL/VBC complex for ubiquitination followed by proteasomal degradation. CP5V induces mitotic inhibition and suppresses cancer cell proliferation .
    CP5V
  • HY-N6782
    Oligomycin
    55+ Cited Publications

    Oxidative Phosphorylation ATP Synthase Fungal Antibiotic Infection Cancer
    Oligomycin, an antifungal antibiotic, is an inhibitor of H +-ATP-synthase. Oligomycin blocks oxidative phosphorylation and the electron transport chain. Oligomycin inhibits HIF-1alpha expression in hypoxic tumor cells .
    Oligomycin
  • HY-130841

    APC Ligands for Target Protein for PROTAC Cancer
    Apcin-A, an Apcin derivative, is an anaphase-promoting complex (APC) inhibitor. Apcin-A interacts strongly with Cdc20, and inhibits the ubiquitination of Cdc20 substrates. Apcin-A can be used to synthesize the PROTAC CP5V (HY-130257) .
    Apcin-A
  • HY-12343

    CID-53347902

    Potassium Channel Cardiovascular Disease
    ML277 (CID-53347902) is a potent and selective activator of K(v)7.1 (KCNQ1) potassium channel activator (EC50=270 nM), rescues function of pathophysiologically important mutant channel complexes in human induced pluripotent stem cell-derived cardiomyocytes .
    ML277
  • HY-156498
    RMC-7977
    2 Publications Verification

    Ras ERK Raf Ribosomal S6 Kinase (RSK) AMPK Apoptosis PARP Cancer
    RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (Kd = 195 nM) and KRAS (G12V) (Kd = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRAS G12C cancer models, and demonstrates good tolerability across various RAS cancer models .
    RMC-7977
  • HY-E70542

    Biochemical Assay Reagents Cardiovascular Disease
    Bovine Factor V/Va can be purified from fresh bovine plasma and used as a source of V/Va in the prothrombinase complex.
    Bovine Factor V/Va
  • HY-W614725

    APC Ligands for Target Protein for PROTAC Cancer
    Apcin-A monohydrochloride, an Apcin derivative, is an anaphase-promoting complex (APC) inhibitor. Apcin-A monohydrochloride interacts strongly with Cdc20, and inhibits the ubiquitination of Cdc20 substrates. Apcin-A monohydrochloride can be used to synthesize the PROTAC CP5V (HY-130257) .
    Apcin-A monohydrochloride
  • HY-155474

    Apoptosis Cancer
    Me4Phen (compound 3) is an oxygen rhenium (V) complex that depletes mitochondrial membrane potential and upregulates intracellular reactive oxygen species (ROS), leading to endoplasmic reticulum stress-mediated necrosis of cancer cells. Me4Phen is highly lipophilic and effectively overcomes Cisplatin (HY-17394) resistance in a variety of cancer cells .
    Me4Phen
  • HY-126634

    Others Infection
    Lyngbyatoxin B is a complex compound in a versatile biosynthetic pathway from the marine cyanobacterium Moorea producens. By heterologously expressing the lyngbyatoxin biosynthetic pathway in Escherichia coli, lyngbyatoxin A (25.6 mg/L) and its precursor indolactam-V (150 mg/L) were successfully produced. This approach confirmed the biosynthetic route of lyngbyatoxin and laid a chemical foundation for future pathway engineering. In addition, the successful production of lyngbyatoxin A in E. coli opens the possibility for heterologous expression and characterization of other cyanobacterial natural products.
    Lyngbyatoxin B
  • HY-169385

    AUTOTACs Androgen Receptor Cancer
    ATC-324 is an bivalent AR (Androgen Receptor) degrader based on the protein degradation technology platform AUTOphagy-TArgeting Chimera (AUTOTAC). ATC-324 induces the formation of AR/p62 complex, leading to autophagy-lysosomal degradation of AR. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa . ATC-324 is composed of target-binding ligand (TBL) Enzalutamide (HY-70002) and p62/SQSTM1 autophagy-targeting ligand (ATL) YT 6-2 analog-1 (HY-169386), connected by Boc-NH-PEG4-CH2CH2NH2 (HY-W008352). Among them, the active control of the target protein ligand is Enzalutamide carboxylic acid (HY-70002B), and the conjugate composed of the autophagy-targeting ligand and the linker is YT 6-2-PEG3-C2-NH2 (HY-169387).
    ATC-324

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: